Emerging retatrutide, a twin -action drug targeting both GLP-1 and GIP receptors, is sparking considerable interest within the weight loss community. Early clinical studies have revealed substantial losses in overall mass and improvements in metabolic markers for patients with obesity . Experts believe this unique approach could mark a key advance